Any current/future new fundraising through debt or equity?

Currently, Camlin Fine Sciences Limited does not have any large CAPEX plans, which suggests limited immediate need for fundraising. The company’s net debt is around Rs. 565 crores as of September 30, 2023, with long-term debt of about Rs. 230 crores repayable over 5 to 7 years. Management indicated uncertainty regarding becoming debt-free, mentioning it could take 2 to 4 years depending on market conditions. They are keeping multiple alternatives in mind due to volatile market conditions but have not disclosed any specific plans for raising new debt or equity in the near term.

Any current/future capex/capital investment/strategic investment?

No large CAPEX is currently planned for the near term. Net debt stands at about Rs. 565 crores, with Rs. 230 crores as long-term debt repayable over 5-7 years. Vanillin project CAPEX incurred is Rs. 290 crores; future payback period now estimated at 4-5 years due to market conditions. For the NegoLyte factory (750 tons capacity), CAPEX is being done by Lockheed Martin. Larger scale Vanillin plant CAPEX and investment responsibility are under ongoing discussions. The company is monitoring market conditions before deciding on future investment strategies.

Future growth expectations in sales/revenue/volumes?

Blends business is expected to grow strongly at 25%-30% annually, driven by stabilized operations and market expansion in North America, Brazil, Mexico, Europe, and Africa. Vanillin business aims to achieve about 90% capacity utilization by FY26, with revenue expected to ramp up over the next 2 years, reaching around Rs. 700-800 crores eventually. Current year focuses on liquidating inventory and starting supplies from awarded contracts from January onwards, with business momentum expected to build from Q4. Performance chemicals segment anticipated to recover gradually, especially with i

Future growth expectations in earnings/operating earnings/profits/EPS?

Blends business expected to grow at 25%-30% annually, driven by robust demand across geographies including Vietnam, Thailand, Europe, and Africa. Performance chemicals segment growth depends on the turnaround of Italian subsidiary and new downstream products like hydroquinone and catechol. Vanillin business aims to ramp up to 90% capacity in two years, targeting gross margins of 15%-25%; payback period for Vanillin project now estimated at 4-5 years due to market conditions. Margin pressure may persist short term if crude oil prices spike sharply; raw material costs have stabilized recently. M

Current/ Expected Orderbook/ Pending Orders?

Camlin Fine Sciences has bid for Vanillin contracts totaling over 4,000 tons. Supplies for awarded contracts are expected to begin from January (next financial year). They are hopeful to secure a substantial portion of these bids within 30 to 45 days after the call. Current Vanillin inventory is valued around Rs. 50 crores, with an additional Rs. 20 crores in Ethyl Vanillin inventory being built. The company expects to liquidate existing Vanillin stock and grow sales through new contracts. Fixed-price contracts are typically for one year duration with limited pricing volatility unles

IN US

Sale is live|00:00:00left today

Camlin Fine Sciences LtdQ3 FY23Chemicals & Petrochemicals

Camlin Fine Sciences Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹138P/E: 1014.3Market Cap: ₹2.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Blends business is expected to grow strongly at 25%-30% annually, driven by stabilized operations and market expansion in North America, Brazil, Mexico, Europe, and Africa.
→Vanillin business aims to achieve about 90% capacity utilization by FY26, with revenue expected to ramp up over the next 2 years, reaching around Rs. 700-800 crores eventually.
→Current year focuses on liquidating inventory and starting supplies from awarded contracts from January onwards, with business momentum expected to build from Q4.
→Performance chemicals segment anticipated to recover gradually, especially with improvements in the Italian subsidiary’s operations, potentially increasing its revenue contribution.
→Growth in aroma segment expected post product validation and contracting phase, with ramp-up expected from Q4 onwards.
→Overall, a cautious but positive outlook with target market share increase and meaningful progress anticipated by FY26.

Margin guidance

Category 3

→Blends business expected to grow at 25%-30% annually, driven by robust demand across geographies including Vietnam, Thailand, Europe, and Africa.
→Performance chemicals segment growth depends on the turnaround of Italian subsidiary and new downstream products like hydroquinone and catechol.
→Vanillin business aims to ramp up to 90% capacity in two years, targeting gross margins of 15%-25%; payback period for Vanillin project now estimated at 4-5 years due to market conditions.
→Margin pressure may persist short term if crude oil prices spike sharply; raw material costs have stabilized recently.
→Market uncertainties and geopolitical factors may impact near-term performance, but Q4 and second half expected to show improvement.
→Debt expected to be managed carefully; no large CAPEX planned, with focus on maintaining financial stability.
→Overall, longer-term growth prospects remain positive with incremental contributions from aroma and performance chemicals alongside blends.

3 more insights locked — sign up free to unlock

Fundraise plans

→Currently, Camlin Fine Sciences Limited does not have any large CAPEX plans, which suggests limited immediate need for fundraising.
→The company’s net debt is around Rs. 565 crores as of September 30, 2023, with long-term debt of about Rs. 230 crores repayable over 5 to 7 years.
→Management indicated uncertainty regarding becoming debt-free, mentioning it could take 2 to 4 years depending on market conditions.
→They are keeping multiple alternatives in mind due to volatile market conditions but have not disclosed any specific plans for raising new debt or equity in the near term.

Order book

→Camlin Fine Sciences has bid for Vanillin contracts totaling over 4,000 tons.
→Supplies for awarded contracts are expected to begin from January (next financial year).
→They are hopeful to secure a substantial portion of these bids within 30 to 45 days after the call.
→Current Vanillin inventory is valued around Rs. 50 crores, with an additional Rs. 20 crores in Ethyl Vanillin inventory being built.
→The company expects to liquidate existing Vanillin stock and grow sales through new contracts.
→Fixed-price contracts are typically for one year duration with limited pricing volatility unless price changes exceed predefined bands.
→No specific broad order book value was disclosed, but bidding activity indicates an improving order flow starting next quarter.

Capex plans

→No large CAPEX is currently planned for the near term.
→Net debt stands at about Rs. 565 crores, with Rs. 230 crores as long-term debt repayable over 5-7 years.
→Vanillin project CAPEX incurred is Rs. 290 crores; future payback period now estimated at 4-5 years due to market conditions.
→For the NegoLyte factory (750 tons capacity), CAPEX is being done by Lockheed Martin.
→Larger scale Vanillin plant CAPEX and investment responsibility are under ongoing discussions.
→The company is monitoring market conditions before deciding on future investment strategies.

How does Camlin Fine Sciences Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Camlin Fine Sciences Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Camlin Fine Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio